

22 November 2023

Dear Cystic Fibrosis Australia Community

We are thrilled to inform you that the Pharmaceutical Benefits Advisory Committee (PBAC) has listed the March 2024 agenda, featuring a crucial discussion on the extension of Trikafta for the 2–5-year age group. In particular, this will provide treatment access to an additional 286 patients.

This is good progress in ensuring that more people have access to the medication they will benefit from.

As advocates for the cystic fibrosis (CF) community, we recognize the significance of early intervention in supporting individuals living with CF. Trikafta, a groundbreaking medication, has already provided transformative benefits for many in various countries worldwide.

Now, it is our collective opportunity to ensure that this life-changing intervention is extended to our youngest CF warriors. By coming together as a community and providing our invaluable feedback, we can actively contribute to shaping the future of CF care in Australia.

We encourage each one of you to share your insights and perspectives. Your feedback is instrumental in reinforcing the importance of expanding Trikafta access to the 2-5-year age group.

Submit your feedback and be part of this pivotal moment now.

[**SUBMIT FEEDBACK HERE**](#)

The consultation period closes on the 31st January 2024.

Let us unite in advocating for the well-being of our little ones. Together, we can make a lasting impact on the landscape of CF care in Australia. We know there is a long way to go to ensure that all people have access to effective therapies, and this is something we must continue to advocate for. Hopefully, this will help continue the momentum of the progress we have seen in Australia.

Thank you for your ongoing support.

Warm regards,

Jo Armstrong

CEO

Cystic Fibrosis Australia